RxDoctor Payments Data

Chad Brock, MD

Psychiatry · Savannah, GANPI 1588691794

Payments from drug & device makers

$15,551in general payments, 2019–2025

Across 878 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Axsome Therapeutics, Inc.$913
  • Neos Therapeutics, LP$754
  • Corium, LLC$710
  • plus $8K from 34 others

What the payments were for

  • Food & beverage$15,539100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,551 in reported general payments places this provider in the 90th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$68,672
Medicare patients
187
Services billed
819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl15$30,835
RexultiBrexpiprazole18$29,781
NuedextaDextromethorphan Hbr/Quinidine12$15,591
Lisdexamfetamine Dimesylate40$10,276
Aripiprazole155$10,199
Lurasidone Hcl12$7,845
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine227$7,119
VyvanseLisdexamfetamine Dimesylate15$6,623
DayvigoLemborexant13$4,850
Duloxetine Hcl139$3,977
Fluvoxamine Maleate41$3,688
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine66$3,628
Tranylcypromine Sulfate12$3,379
Venlafaxine Hcl ErVenlafaxine Hcl101$2,904
Methylphenidate Hcl78$2,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$2,500$30,83515 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,352$29,78118 claims
Avanir Pharmaceuticals, Inc.Nuedexta$445$15,59112 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$1,081$6,62315 claims
Eisai Inc.Dayvigo$154$4,85013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →